Exclusive production of gentamicin C1a from micromonospora purpurea by metabolic engineering

5Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.

Abstract

Gentamicin C1a is an important precursor to the synthesis of etimicin, a potent antibiotic. Wild type Micromonospora purpurea Gb1008 produces gentamicin C1a, besides four other gentamicin C components: C1, C2, C2a, and C2b. While the previously reported engineered strain M. purpurea GK1101 can produce relatively high titers of C1a by blocking the genK pathway, a small amount of undesirable C2b is still being synthesized in cells. Gene genL (orf6255) is reported to be responsible for converting C1a to C2b and C2 to C1 in Micromonospora echinospora ATCC15835. In this work, we identify the genL that is also responsible for the same methylation in Micromonospora purpurea. Based on M. purpurea GK1101, we construct a new strain with genL inactivated and show that no C2b is produced in this strain. Therefore, we successfully engineer a strain of M. purpurea that solely produces gentamicin C1a. This strain can potentially be used in the industrial production of C1a for the synthesis of etimicin.

Cite

CITATION STYLE

APA

Wei, Z., Shi, X., Lian, R., Wang, W., Hong, W., & Guo, S. (2019). Exclusive production of gentamicin C1a from micromonospora purpurea by metabolic engineering. Antibiotics, 8(4). https://doi.org/10.3390/antibiotics8040267

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free